Skip to main content
HYPHENS PHARMA INTERNATIONAL LIMITED logo

HYPHENS PHARMA INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · 1J5 ISIN · SG1EE4000006 SGX Wholesale and retail trade
Filings indexed 30 across all filing types
Latest filing 2026-04-29 M&A Activity
Country SG Singapore
Listing SGX 1J5

About HYPHENS PHARMA INTERNATIONAL LIMITED

https://www.hyphensgroup.com/

HYPHENS PHARMA INTERNATIONAL LIMITED is a specialty pharmaceutical and consumer healthcare group. The company's core activities encompass the marketing and distribution of specialty pharmaceutical products, alongside the development and commercialization of its proprietary dermatological and health supplement brands, such as Ceradan and TDF. Additionally, it operates a medical hypermart and digital platforms. The group maintains a significant presence across ASEAN countries, serving as an exclusive distributor for various products in the region, including Wynzora Cream in Southeast Asia, and extending its proprietary brands like Ceradan to markets including the Middle East.

Recent filings

Filing Released Lang Actions
Asset Acquisitions and Disposals::Completion of Proposed Acquisition of the Tranche 3 Sale Shares of 18% in Ardence Pharma Sdn Bhd
M&A Activity Classification · 95% confidence The document is a formal SGX announcement detailing the completion of an acquisition transaction (Tranche 3 completion of 18% share capital in Ardence Pharma), including consideration, financial effects under Chapter 10 of the SGX Catalist Rules, sources of funds, and other transaction-specific disclosures. This is clearly a merger & acquisition activity announcement rather than an annual report, earnings release, or board change notice. Therefore, it is classified as an M&A Activity (Code: TAR).
2026-04-29 English
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Change of Director's Interest - Lim See Wah
Regulatory Filings
2026-04-22 English
General Announcement::Responses to Substantial and Relevant Questions from Shareholders on Annual Report 2025
Regulatory Filings
2026-04-21 English
Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Change of Director's Interest - Lim See Wah
Regulatory Filings
2026-04-21 English
Annual Reports and Related Documents::
Regulatory Filings
2026-04-17 English
Cash Dividend/ Distribution::Mandatory
Regulatory Filings
2026-04-10 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.